How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about cabotegravir

Marketing authorisation indication

2.1

Cabotegravir (Apretude, ViiV Healthcare) is indicated 'in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg'.

Dosage in the marketing authorisation

2.2

The dosage schedule is available in the summary of product characteristics for cabotegravir.

Price

2.3

The proposed list price of 1 vial of prolonged-release suspension for injection and for a 30-day pack of oral tablets is commercial in confidence and cannot be reported here.

2.4

The company has a commercial arrangement. This makes cabotegravir available to the NHS with a discount. The size of the discount is commercial in confidence.